Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Recruiting now · Phase 2/Phase 3

Conditions studied: Duchenne Muscular Dystrophy

In brief

This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.

Key facts

Study ID

NCT03373968

Run by

Italfarmaco

People needed

206

Starts

2017-10-24

Expected to finish

2029-12-01

Last updated by the study team

2026-01-21

Who can join

Age: 7 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Must have participated in one of the previous studies with GIVINOSTAT in DMD and have attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and met:
• all the inclusion criteria and none of the exclusion criteria,
• had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in the range ≤5% or >30%, i.e. included in"off-target" group,
• never been randomized because, the enrollment in the off target group was completed.
• Aged ≥6 years old;
• Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to localregulations);
• Subjects must be willing to use adequate contraception:
• Contraceptive methods must since the previous GIVINOSTAT study through 3 months after the last dose of study drug, and include the following:
• True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject.
• Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
• Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral,
• transdermal, injectable or implanted steroid-basedcontraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such asfor example cervical cap with spermicide jelly.

You may not qualify if…

• Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to be enrolled in this study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed;
• Use of any current investigational drug other than Givinostat;
• Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
• Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
• Have platelets count, White Blood Cell and Hemoglobin at screening < Lower Limit of Normal (LLN)* (for abnormal screening laboratory test results (<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still <LLN, then exclusionary);
• Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit* (for abnormal screening laboratory test results (>300 mg/dL), the triglycerides will be repeated once; if the repeat test result is still >300 mg/dL, then exclusionary);
• Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN) at screening visit*. If the value is >2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 x ULN, the subject should be excluded);
• Have heart failure (New York Heart Association Class III or IV)
• Have a current liver disease or impairment, including but not limited to an elevated total bilirubin* (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's;
• Have a baseline QTcF >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
• Have a psychiatric illness/social situation rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures.
• Have any hypersensitivity to the components of study medication;
• Have a sorbitol intolerance or sorbitol malabsorption or have the hereditary form of fructose intolerance.
• the Investigators to evaluate these exclusion criteria can use the laboratory results obtained within 5 months from V1, to allow the continuity of the treatment. It is worth noting, as soon as the site will receive the laboratory results done in screening/baseline (Visit 1) visit they will check the GIVINOSTAT dose and modify it as per protocol safety rules and/or dosage modifications rules.

Where it is running

• Ospedale Pediatrico Bambino Gesù, Malattie Neuromuscolari e Neurodegenerative — Roma, Italy (enrolling)
• U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative, Building 16 - ground floor IRCCS Istituto Giannina Gaslini, — Genova, Italy (enrolling)
• Hospital Materno-Infantil — Barcelona, Spain (enrolling)
• Child Health Research Institute — Gainesville, Florida, United States
• MD Rare Disease Research, LLC — Atlanta, Georgia, United States
• University of Iowa Children's Hospital — Iowa City, Iowa, United States
• Washington University School of Medicine in St Louis Department of Neurology 660 S.Euclid Avenue, Campus Box 8111 — St Louis, Missouri, United States
• Shriners Hospitals for Children — Portland, Oregon, United States
• The Children's Hospital of Philadelphia Colket Translational Research Building — Philadelphia, Pennsylvania, United States
• Virginia Commonwealth University Childrens Hospital of Richmond at — Richmond, Virginia, United States
• University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology — Leuven, Belgium
• Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN) — Liège, Belgium
• Kinsmen Research Centre - Alberta Children's Hospital — Calgary, Alberta, Canada
• The University of British Columbia, Children's and Womens Health Centre of BC Branch — Vancouver, British Columbia, Canada
• Holland Bloorview Kids Rehabilitation Hospital — Toronto, Ontario, Canada
• CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest — Nantes, France
• Hôpital Armand Trousseau I-Motion - Plateforme d'essais cliniques pédiatriques Bâtiment Lemariey - Porte 20 * 2ème étage 26 Avenue du Dr Arnold Nette — Paris, France
• Universitätsklinikum Essen - Kinder-und Jugendmedizin Neuropadiatrie — Essen, Germany
• Klinik- und Poliklinik fur Kinder- und Jugendmedizin, Universitatsklinikum HamburgEppendorf, Martinistr. 52 — Hamburg, Germany
• Klinikum der Universitat Munchen, Campus Innenstadt, Lindwurmstr. 4 — München, Germany
• Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14 — Petah Tikva, Israel
• A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari — Messina, Italy
• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica — Milan, Italy
• IRCCS Istituto Neurologico Carlo Besta — Milan, Italy
• Centro Clinico NeMO Fondazione Serena ONLUS Area SUD — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.